A landmark PET/CT investigation linking mitochondrial and receptor alterations to ALS disease progression.
This peer-reviewed study, published in Neurobiology of Disease, demonstrates how advanced preclinical and translational PET/CT imaging can uncover the molecular mechanisms driving neurodegeneration in Amyotrophic Lateral Sclerosis (ALS). Using radiotracers [¹⁸F]BCPP-EF, [¹¹C]SA4503, and [¹¹C]UCB-J, the research evaluated mitochondrial complex 1 (MC1), sigma-1 receptor (S1R), and synaptic vesicle 2A (SV2A) expression in ALS patients versus healthy controls. Results revealed significant loss of MC1 and S1R in the amygdala, hippocampus, and insular cortex, correlating with disease severity and functional decline. This study forms part of a highly successful MIND MAPS collaboration. MIND MAPS is a pre-competitive consortium aiming to develop molecular markers of neurodegeneration, led by Perceptive Discovery and including AbbVie, Biogen, Pfizer, Takeda and BMS, as well as academic collaborators from leading UK universities (Imperial College, King’s College, University College London, University of Cambridge, University of Exeter). Perceptive Discovery is the world’s leading company providing translational imaging services for industry and academic collaborators.
Why Read this Publication:
